Do the results and approval based on ADAURA trial suggest a role for adjuvant osimertinib in patients with stage IIIB-C, EGFR mutant patients treated with concurrent chemoradiation?  


Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution